BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Parienti JJ, Prazuck T, Peyro-Saint-Paul L, Fournier A, Valentin C, Brucato S, Verdon R, Sève A, Colin M, Lesne F, Guinard J, Ar Gouilh M, Dina J, Vabret A, Hocqueloux L. Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial. EClinicalMedicine 2021;38:100993. [PMID: 34222849 DOI: 10.1016/j.eclinm.2021.100993] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
Number Citing Articles
1 Polo R, García-albéniz X, Terán C, Morales M, Rial-crestelo D, Garcinuño M, García del Toro M, Hita C, Gómez-sirvent J, Buzón L, Díaz de Santiago A, Pérez Arellano J, Sanz J, Bachiller P, Martínez Alfaro E, Díaz-brito V, Masiá M, Hernández-torres A, Guerra J, Santos J, Arazo P, Muñoz L, Arribas J, Martínez de Salazar P, Moreno S, Hernán M, Del Amo J, del Amo J, Rosa Polo, Moreno S, Berenguer J, Martínez E, Hernán M, Martínez de Salazar P, García de Albéniz X, Iradier M, Jarrín I, Zamora J, Rivero A, Menéndez C, Conde E, Montes J, Terán C, Flores B, Elena Choque M, Peñaranda J, Gorena G, Herrera M, Farfán M, Moya D, Camacho J, Ordoñez J, Mayora J, Farfán B, Morales M, Benítez M, Bolaños R, Colina J, Pulido F, Rubio R, Bisbal O, de Lagarde M, Epalza C, Lillo-díaz C, Martínez R, Sebastián Pedrodomingo M, de la Hoz C, Sánchez D, Cristina Antolí A, Grande C, María Astudillo D, Deltoro MG, Chirivella JI, Hita C, Montero MC, Ruíz J, Alonso MM, Alemán MR, López AM, García D, Pelazas R, Recio PG, Martínez-vera F, Muñoz A, De la Fuente S, Muñoz A, Vázquez JM, Carranza C, Hernández M, Jaén N, Lavilla C, Pisos E, Suárez L, Santos IDL, García-fraile L, Gutiérrez Á, Bautista A, Muñoz S, de los Santos JMA, Ferreira EM, Carrero A, Mateos F, Blanch JJ, Solis García JE, Sanmartí M, Gómez R, Moreno E, Álvarez MC, García-abellán J, Gutiérrez F, Padilla S, Estañ G, Moral E, Marín S, Roura AE, Pareja A, Martín Regidor M, Gutiérrez E, Valdivia LJ, Capón P, Domínguez A, Moreno A, Ruiz L, Garrido R, Cecilio Á, Fenoll R, Peregrina J, Anguita F, Martín L, Dronda F, Häemmerle J, Crespillo C, Flores J, Castellano L, Dueñas C, Fernández LR, Zapico G, Tasias M, Berrocal P, Campo C, Baño JR, Domínguez-castellano Á, Ríos-villegas MJ, Noguera-julian A, Fortuny C, Ríos-barnés M, Hernández-pérez G, Sánchez-ledesma M, Carbonell C, Sánchez-navarro J, del Hoyo CS, Morán Y, Cabello A, Carrillo I, Górgolas M, Antela A, Losada E, Domínguez MJ, Mariño AI, Sánchez-trigo S, Martínez-varela S, Aguilar E, González-lama J, Plata A, Rubio MT, Marín M, Zardoya L, Mendoza DD, Gutiérrez A, Coll R, Sanjoaquín I, Loscos S, Geijo M, Belinchon O, Bernal E, Deschamps-perdomo Á, Arranz JA, Borobia A, Knobel H, Artero A, Rivero M, Galindo MJ, Cepeda C, Blanco JR, Estrada V, Lecuona A, Gómez J, Asensi V, Cervero M. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers. Clinical Microbiology and Infection 2022. [DOI: 10.1016/j.cmi.2022.07.006] [Reference Citation Analysis]
2 Marjot T, Eberhardt CS, Boettler T, Belli LS, Berenguer M, Buti M, Jalan R, Mondelli MU, Moreau R, Shouval D, Berg T, Cornberg M. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper. J Hepatol 2022:S0168-8278(22)02942-7. [PMID: 35868584 DOI: 10.1016/j.jhep.2022.07.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco-Hidalgo RM, Casabona J, Domingo P, Navarro J, Imaz A, Deig E, Navarro G, Llibre JM, Miro JM; PISCIS study group . Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study. J Antimicrob Chemother 2022:dkac177. [PMID: 35678461 DOI: 10.1093/jac/dkac177] [Reference Citation Analysis]
4 Nadeali Z, Rezaei FM, Aria H, Nikpour P. Possible role of pannexin 1 channels and purinergic receptors in the pathogenesis and mechanism of action of SARS-CoV-2 and therapeutic potential of targeting them in COVID-19. Life Sciences 2022. [DOI: 10.1016/j.lfs.2022.120482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mazzitelli M, Trunfio M, Sasset L, Leoni D, Castelli E, Lo Menzo S, Gardin S, Putaggio C, Brundu M, Garzotto P, Cattelan AM. Factors Associated with Severe COVID-19 and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA. Viruses 2022;14:493. [DOI: 10.3390/v14030493] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lee MJ, Nori A, Fidler S, Kulasegaram R, Fox J, Smith C; RECEDE-C19 study. Response to 'The use of tenofovir in patients with COVID-19'. HIV Med 2022. [PMID: 35194929 DOI: 10.1111/hiv.13278] [Reference Citation Analysis]
7 Del Amo J, Polo R, Moreno S, Jarrín I, Hernán MA. SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment. AIDS 2022;36:161-8. [PMID: 34934017 DOI: 10.1097/QAD.0000000000003132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
8 Del Amo J, Diaz A, Polo R. The impact of coronavirus disease 2019 on people with HIV. Curr Opin Infect Dis 2022;35:9-14. [PMID: 34812744 DOI: 10.1097/QCO.0000000000000799] [Reference Citation Analysis]
9 Kow CS, Ramachandram DS, Hasan SS. The use of tenofovir in patients with COVID-19. HIV Med 2022. [PMID: 35023263 DOI: 10.1111/hiv.13228] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Gaitán-Duarte HG, Álvarez-Moreno C, Rincón-Rodríguez CJ, Yomayusa-González N, Cortés JA, Villar JC, Bravo-Ojeda JS, García-Peña A, Adarme-Jaimes W, Rodríguez-Romero VA, Villate-Soto SL, Buitrago G, Chacón-Sarmiento J, Macias-Quintero M, Vaca CP, Gómez-Restrepo C, Rodríguez-Malagón N. Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine 2022;43:101242. [PMID: 34957385 DOI: 10.1016/j.eclinm.2021.101242] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Wang Z, Yang L. Broad-spectrum prodrugs with anti-SARS-CoV-2 activities: Strategies, benefits, and challenges. J Med Virol 2021. [PMID: 34897729 DOI: 10.1002/jmv.27517] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Díaz NA, de Miguel R, Agüero F, Sued O, Arribas JR, Ambrosioni J; Hospital Clinic COVID-19 in HIV Investigators. Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data. Infect Dis Ther 2021. [PMID: 34709579 DOI: 10.1007/s40121-021-00547-y] [Reference Citation Analysis]
13 Boffito M, Waters L. More evidence for worse COVID-19 outcomes in people with HIV. Lancet HIV 2021;8:e661-2. [PMID: 34655548 DOI: 10.1016/S2352-3018(21)00272-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yang X, Sun J, Patel RC, Zhang J, Guo S, Zheng Q, Olex AL, Olatosi B, Weissman SB, Islam JY, Chute CG, Haendel M, Kirk GD, Li X; National COVID Cohort Collaborative Consortium. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. Lancet HIV 2021;8:e690-700. [PMID: 34655550 DOI: 10.1016/S2352-3018(21)00239-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]